Article
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2006
Argiris Athanassios, Hensing Thomas, Yeldandi Anjana, Patel Smita, Raji Adekunle, Sturgis Charles, Masters Gregory, Gooding William, Pins Michael, Kolesar Jill
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been introduced in the standard therapy of non-small-cell lung cancer (NSCLC), but they benefit a minority of patients. The study of molecular markers may identify the subset of patients who are the most appropria...
Topics
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- DNA, Neoplasm
- Disease Progression
- ErbB Receptors
- Exons
- Female
- Follow-Up Studies
- Gefitinib
- Humans
- Immunohistochemistry